Pulmonary arterial hypertension (PAH) is a severe condition that affects the arteries in the lungs and the right side of the heart. One of the significant advancements in treating this condition has been the development of Selexipag, a nonprostanoid prostacyclin receptor (IP receptor) agonist. The efficacy of Selexipag in managing PAH is well-documented, offering patients improved outcomes and quality of life. Central to the synthesis of Selexipag is a key chemical intermediate: 4-(Isopropylamino)butanol (CAS: 42042-71-7). This compound serves as a crucial building block, enabling the complex molecular architecture of Selexipag to be constructed. NINGBO INNO PHARMCHEM CO.,LTD. plays a vital role as a reliable supplier of high-purity 4-(Isopropylamino)butanol, ensuring that pharmaceutical manufacturers have access to the quality materials needed for this critical drug. Understanding the chemical synthesis pathways for Selexipag intermediates, such as 4-(Isopropylamino)butanol, is paramount for consistent production and pharmaceutical innovation. The demand for efficient and cost-effective chemical synthesis methods for these intermediates is ever-increasing, driving research into optimized production processes. By providing a dependable source for this essential intermediate, NINGBO INNO PHARMCHEM CO.,LTD. contributes significantly to the pharmaceutical supply chain, supporting the availability of treatments for patients with pulmonary arterial hypertension. The careful control over purity and yield during the synthesis of 4-(Isopropylamino)butanol directly impacts the final drug product's quality and efficacy.